From Pig to Patient: XenoTherapeutics Completes First Cohort of Patients in First US Clinical Trial of Live-Cell Xenotransplant; Evidence of Safety and Efficacy Allows for Accelerated Patient Enrollment
November 05, 2020 09:24 ET | XenoTherapeutics
BOSTON, MA, Nov. 05, 2020 (GLOBE NEWSWIRE) -- XenoTherapeutics, a clinical-stage cell and gene therapy company engineering immune-compatible cells, tissues, and organs, has completed the first of...
XenoTherapeutics Granted U.S. Patent Covering Method of Producing Clinically Acceptable Porcine Cells, Tissues, and Organs for Human Xenotransplantation
October 15, 2020 10:03 ET | XenoTherapeutics
BOSTON, MA, Oct. 15, 2020 (GLOBE NEWSWIRE) -- XenoTherapeutics, a clinical-stage cell and gene therapy company engineering immune-compatible cells, tissues, and organs, announced that the U.S....
XenoTherapeutics Welcomes Michael Yaremchuk as Chief Medical Officer
February 26, 2020 15:00 ET | XenoTherapeutics
Boston, Feb. 26, 2020 (GLOBE NEWSWIRE) -- XenoTherapeutics, a clinical-stage biotechnology company developing alternative gene therapies in xenotransplantation to supply living cells, tissues, and...